Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.9K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.9K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Cholinesterases: Distribution and Function01:22

Cholinesterases: Distribution and Function

1.3K
Cholinesterases are a group of serine hydrolase enzymes that play a crucial role in the breakdown of choline esters. The two primary types of cholinesterases are acetylcholinesterases (AChEs) and butyrylcholinesterase (BuChEs), which differ in their distribution, function, and substrate specificity. AChEs, also known as true cholinesterases, specifically hydrolyze acetylcholine, while BuChEs, often referred to as pseudocholinesterases, can hydrolyze various choline esters, including...
1.3K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.3K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2,3-Dihydroquinazolin-4(1H)-one derivatives as potent aldose reductase inhibitors: a combined experimental and computational study.

Bioorganic chemistry·2026
Same author

Integrative Transcriptomic, Network, and Machine Learning Analyses Identify Genistein and Resveratrol-Associated Therapeutic Targets in Alzheimer's Disease.

Molecular neurobiology·2026
Same author

Novel pyridazinone-based N-phenylacetamides as α-glucosidase-selective and dual α-glucosidase/aldose reductase inhibitors: Synthesis, SAR analysis, and cytotoxicity evaluation.

Bioorganic chemistry·2026
Same author

Integrative Bioinformatics, Experimental Validation, and Interpretable Machine Learning Reveal Oxyresveratrol-Mediated Protection Against Cadmium-Induced Lung Adenocarcinoma-Related Transcriptional Dysregulation.

Environmental toxicology·2026
Same author

Exercise-induced microRNAs: molecular pathways and adaptive remodeling of skeletal muscle.

Pflugers Archiv : European journal of physiology·2026
Same author

Design, Synthesis, and Enantioselective Cholinesterase Inhibition of Novel Chiral Anthranilic Diamide Derivatives: In Vitro and In Silico Studies.

Chirality·2026

Related Experiment Video

Updated: Apr 24, 2026

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

6.4K

Evaluation of pyrimidine-based compounds as AChE and BChE inhibitors: in vitro inhibition, molecular modeling, and

Zuhal Alım1,2, Yeliz Demir3,4

  • 1Department of Chemistry, Faculty of Arts and Sciences, Kırşehir Ahi Evran University, Kırşehir, 40100, Türkiye.

Naunyn-Schmiedeberg'S Archives of Pharmacology
|April 23, 2026
PubMed
Summary

Seven pyrimidine derivatives were tested as inhibitors for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), enzymes relevant to Alzheimer's disease (AD) treatment. Compound 6 showed strong selectivity for AChE inhibition.

Keywords:
AcetylcholinesteraseButyrylcholinesteraseInhibitionMolecular dockingPyrimidine

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K
NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

9.2K

Related Experiment Videos

Last Updated: Apr 24, 2026

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

6.4K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K
NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

9.2K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing dementia, posing a significant global health challenge.
  • Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors are key therapeutic targets for AD due to their role in neurotransmitter modulation.
  • Pyrimidine derivatives have demonstrated potential in improving cognitive functions and treating neurodegenerative diseases.

Purpose of the Study:

  • To investigate the inhibitory potential of seven novel pyrimidine derivatives against AChE and BChE.
  • To evaluate the structure-activity relationship (SAR) of these compounds for potential AD therapeutics.
  • To explore the binding interactions of potent derivatives within the enzyme active sites using molecular modeling.

Main Methods:

  • In vitro enzyme inhibition assays were performed to determine IC50 values for compounds 1-7 against AChE and BChE.
  • In silico molecular modeling techniques were employed to visualize and analyze enzyme-inhibitor interactions.
  • Correlation and regression analyses were used to establish structure-activity relationships.

Main Results:

  • All seven pyrimidine derivatives (1-7) exhibited potent inhibitory effects against AChE and BChE, with IC50 values ranging from 14.89 to 77.70 nM.
  • Compound 6 demonstrated the strongest inhibition against AChE (IC50: 14.89 nM) with approximately 24-fold selectivity over BChE (IC50: 357 nM).
  • Compounds 1 and 3 showed significant inhibition against BChE, suggesting multiple binding modes within the active site, while compounds 6 and 7 displayed favorable interactions with the AChE active site.

Conclusions:

  • The studied pyrimidine derivatives represent promising candidates for the development of novel Alzheimer's disease therapeutics targeting AChE and BChE.
  • Compound 6 is a highly selective AChE inhibitor with potential for further development.
  • The identified SAR provides a foundation for designing more potent and selective inhibitors for neurodegenerative disease treatment.